Bahl & Gaynor’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $542K | Sell |
5,995
-50
| -0.8% | -$4.59K | ﹤0.01% | 273 |
|
|
2025
Q4 | $544K | Hold |
6,045
| – | – | ﹤0.01% | 278 |
|
|
2025
Q3 | $595K | Sell |
6,045
-440
| -7% | -$43.6K | ﹤0.01% | 271 |
|
|
2025
Q2 | $591K | Sell |
6,485
-61
| -0.9% | -$5.9K | ﹤0.01% | 270 |
|
|
2025
Q1 | $741K | Sell |
6,546
-2
| -0% | -$214 | ﹤0.01% | 256 |
|
|
2024
Q4 | $692K | Hold |
6,548
| – | – | ﹤0.01% | 262 |
|
|
2024
Q3 | $707K | Sell |
6,548
-2,166
| -25% | -$236K | ﹤0.01% | 265 |
|
|
2024
Q2 | $946K | Buy |
8,714
+311
| +4% | +$36.7K | 0.01% | 247 |
|
|
2024
Q1 | $1.11M | Buy |
8,403
+42
| +0.5% | +$5.25K | 0.01% | 240 |
|
|
2023
Q4 | $1.02M | Sell |
8,361
-71
| -0.8% | -$7.92K | 0.01% | 242 |
|
|
2023
Q3 | $946K | Sell |
8,432
-262
| -3% | -$33.3K | 0.01% | 242 |
|
|
2023
Q2 | $1.27M | Sell |
8,694
-16
| -0.2% | -$2.17K | 0.01% | 232 |
|
|
2023
Q1 | $1.13M | Sell |
8,710
-18
| -0.2% | -$2.26K | 0.01% | 233 |
|
|
2022
Q4 | $1.11M | Sell |
8,728
-327
| -4% | -$37.9K | 0.01% | 233 |
|
|
2022
Q3 | $947K | Sell |
9,055
-703
| -7% | -$77.1K | 0.01% | 237 |
|
|
2022
Q2 | $1.02M | Buy |
9,758
+14
| +0.1% | +$1.66K | 0.01% | 245 |
|
|
2022
Q1 | $1.25M | Sell |
9,744
-972
| -9% | -$117K | 0.01% | 242 |
|
|
2021
Q4 | $1.32M | Hold |
10,716
| – | – | 0.01% | 246 |
|
|
2021
Q3 | $1.52M | Sell |
10,716
-289
| -3% | -$42.5K | 0.01% | 240 |
|
|
2021
Q2 | $1.72M | Hold |
11,005
| – | – | 0.01% | 240 |
|
|
2021
Q1 | $1.71M | Sell |
11,005
-25
| -0.2% | -$3.87K | 0.01% | 241 |
|
|
2020
Q4 | $1.65M | Buy |
11,030
+371
| +3% | +$52.4K | 0.01% | 242 |
|
|
2020
Q3 | $1.41M | Sell |
10,659
-618
| -5% | -$80.7K | 0.01% | 244 |
|
|
2020
Q2 | $1.31M | Sell |
11,277
-562
| -5% | -$64.8K | 0.01% | 244 |
|
|
2020
Q1 | $1.16M | Sell |
11,839
-334
| -3% | -$43.8K | 0.01% | 244 |
|
|
2019
Q4 | $1.77M | Sell |
12,173
-77
| -0.6% | -$10.6K | 0.01% | 243 |
|
|
2019
Q3 | $1.63M | Buy |
12,250
+144
| +1% | +$18.6K | 0.01% | 243 |
|
|
2019
Q2 | $1.38M | Buy |
12,106
+114
| +1% | +$13.4K | 0.01% | 255 |
|
|
2019
Q1 | $1.49M | Hold |
11,992
| – | – | 0.01% | 240 |
|
|
2018
Q4 | $1.21M | Sell |
11,992
-330
| -3% | -$37.1K | 0.01% | 239 |
|
|
2018
Q3 | $1.57M | Sell |
12,322
-195
| -2% | -$23.2K | 0.02% | 237 |
|
|
2018
Q2 | $1.35M | Buy |
12,517
+195
| +2% | +$21.2K | 0.01% | 250 |
|
|
2018
Q1 | $1.3M | Hold |
12,322
| – | – | 0.01% | 249 |
|
|
2017
Q4 | $1.44M | Hold |
12,322
| – | – | 0.01% | 245 |
|
|
2017
Q3 | $1.4M | Sell |
12,322
-386
| -3% | -$44.6K | 0.02% | 234 |
|
|
2017
Q2 | $1.58M | Sell |
12,708
-272
| -2% | -$32.2K | 0.02% | 211 |
|
|
2017
Q1 | $1.54M | Buy |
12,980
+29
| +0.2% | +$3.29K | 0.02% | 209 |
|
|
2016
Q4 | $1.3M | Sell |
12,951
-16
| -0.1% | -$1.72K | 0.02% | 218 |
|
|
2016
Q3 | $1.64M | Sell |
12,967
-1
| -0% | -$124 | 0.02% | 182 |
|
|
2016
Q2 | $1.52M | Sell |
12,968
-12
| -0.1% | -$1.36K | 0.02% | 185 |
|
|
2016
Q1 | $1.34M | Buy |
12,980
+29
| +0.2% | +$2.81K | 0.02% | 197 |
|
|
2015
Q4 | $1.29M | Sell |
12,951
-248
| -2% | -$24.3K | 0.02% | 201 |
|
|
2015
Q3 | $1.2M | Hold |
13,199
| – | – | 0.02% | 206 |
|
|
2015
Q2 | $1.4M | Sell |
13,199
-102
| -0.8% | -$11.3K | 0.02% | 204 |
|
|
2015
Q1 | $1.52M | Buy |
13,301
+41
| +0.3% | +$4.68K | 0.02% | 190 |
|
|
2014
Q4 | $1.46M | Sell |
13,260
-103
| -0.8% | -$10.9K | 0.02% | 192 |
|
|
2014
Q3 | $1.3M | Sell |
13,363
-361
| -3% | -$35.5K | 0.02% | 197 |
|
|
2014
Q2 | $1.38M | Sell |
13,724
-9,822
| -42% | -$958K | 0.02% | 199 |
|
|
2014
Q1 | $2.16M | Buy |
23,546
+694
| +3% | +$64K | 0.03% | 167 |
|
|
2013
Q4 | $2.07M | Buy |
22,852
+27
| +0.1% | +$2.34K | 0.03% | 168 |
|
|
2013
Q3 | $1.82M | Buy |
22,825
+31
| +0.1% | +$2.44K | 0.03% | 165 |
|
|
2013
Q2 | $1.66M | Buy |
+22,794
| New | +$1.7M | 0.03% | 170 |
|
Other funds holding ZBH
VCM
VPM
Bahl & Gaynor's ZBH Position: Q1 2026 in Review
Bahl & Gaynor reduced its Zimmer Biomet (ZBH) stake by 0.83% in Q1 2026, selling an estimated $4.59K and leaving 5,995 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #273.
Bahl & Gaynor first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.16M in Q1 2014. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Bahl & Gaynor held 5,995 shares of Zimmer Biomet worth $542K as of Q1 2026.
- Bahl & Gaynor sold 50 Zimmer Biomet shares in Q1 2026, an estimated $4.59K.
- Zimmer Biomet made up ﹤0.01% of Bahl & Gaynor's portfolio in Q1 2026, its #273 holding.
- Bahl & Gaynor first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
- Bahl & Gaynor's Zimmer Biomet position peaked at $2.16M in Q1 2014.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Bahl & Gaynor's 13F filing for Q1 2026, filed 7 May 2026.